Ipca Laboratories Ltd

Ipca Laboratories Ltd

₹ 1,240 2.88%
28 Mar 4:01 p.m.
About

Ipca Laboratories is engaged in the manufacturing and marketing of pharmaceuticals.(Source : 201903 Annual Report Page No: 68)

Key Points

Integrated nature of operations
Ipca Laboratories is a fully-integrated pharmaceutical company that manufactures over 350 formulations and 80 APIs for various therapeutic segments. [1]
IPCA is among India’s top 20 pharmaceutical companies. [2]

Business segments FY22:
API Business (25%) [3]
Ipca produces over 80 APIs, nearly 79% of the APIs and Intermediates business is from exports making them one of India’s top exporters of APIs, serving over 100 countries around the globe. The core strategic focus has been on backward integration, resulting in superior supply chain reliability and cost competitiveness [4] [1] [5]

  • Market Cap 31,647 Cr.
  • Current Price 1,240
  • High / Low 1,264 / 670
  • Stock P/E 61.7
  • Book Value 242
  • Dividend Yield 0.32 %
  • ROCE 11.2 %
  • ROE 8.04 %
  • Face Value 1.00

Pros

Cons

  • Company might be capitalizing the interest cost
  • Dividend payout has been low at 14.0% of profits over last 3 years

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
1,410 1,115 1,566 1,544 1,430 1,289 1,586 1,601 1,546 1,512 1,585 2,034 2,053
1,045 886 1,152 1,184 1,123 1,070 1,317 1,341 1,330 1,331 1,278 1,713 1,722
Operating Profit 365 229 414 360 308 219 269 260 216 181 308 321 331
OPM % 26% 21% 26% 23% 22% 17% 17% 16% 14% 12% 19% 16% 16%
15 20 21 18 12 15 22 36 31 36 45 39 90
Interest 2 2 2 1 1 3 7 9 11 18 31 44 33
Depreciation 54 52 56 57 59 61 62 64 67 70 69 90 100
Profit before tax 324 195 377 320 260 170 223 223 169 129 252 225 289
Tax % 17% 16% 19% 21% 22% 17% 33% 35% 32% 37% 34% 39% 23%
268 161 307 252 198 132 145 146 110 78 164 136 221
EPS in Rs 10.46 6.36 12.09 9.86 7.74 5.13 5.64 5.67 4.25 3.02 6.42 5.72 7.09
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
2,359 2,813 3,282 3,144 2,867 3,156 3,258 3,746 4,619 5,395 5,797 6,204 7,184
1,894 2,248 2,539 2,604 2,573 2,705 2,803 3,051 3,715 3,843 4,472 5,272 6,042
Operating Profit 465 565 743 541 294 451 455 695 904 1,552 1,325 932 1,141
OPM % 20% 20% 23% 17% 10% 14% 14% 19% 20% 29% 23% 15% 16%
11 13 21 32 21 11 41 56 65 59 54 123 210
Interest 44 36 30 32 35 27 28 22 20 12 11 48 127
Depreciation 67 87 103 180 163 173 178 182 210 209 232 262 329
Profit before tax 364 454 631 361 117 262 291 546 739 1,389 1,136 745 896
Tax % 24% 29% 24% 28% 18% 26% 18% 19% 18% 17% 20% 34%
277 324 479 254 93 195 239 442 604 1,141 890 479 600
EPS in Rs 11.01 12.82 18.96 10.07 3.69 7.71 9.49 17.60 23.99 44.94 34.85 18.58 22.25
Dividend Payout % 15% 16% 13% 5% 0% 6% 5% 9% 10% 9% 11% 22%
Compounded Sales Growth
10 Years: 8%
5 Years: 14%
3 Years: 10%
TTM: 19%
Compounded Profit Growth
10 Years: 3%
5 Years: 14%
3 Years: -9%
TTM: -2%
Stock Price CAGR
10 Years: 11%
5 Years: 20%
3 Years: 10%
1 Year: 57%
Return on Equity
10 Years: 15%
5 Years: 17%
3 Years: 17%
Last Year: 8%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Sep 2023
Equity Capital 25 25 25 25 25 25 25 25 25 25 25 25 25
Reserves 1,229 1,529 1,934 2,183 2,234 2,430 2,663 3,097 3,590 4,676 5,439 5,817 6,123
601 617 603 935 867 716 628 465 501 265 807 1,481 1,987
472 526 648 669 765 788 799 961 1,142 1,099 1,349 1,300 3,248
Total Liabilities 2,327 2,697 3,211 3,812 3,892 3,960 4,116 4,549 5,258 6,066 7,622 8,623 11,384
944 1,104 1,354 1,800 2,014 1,983 1,953 1,940 2,059 2,072 2,402 2,751 4,588
CWIP 95 129 165 267 129 95 73 66 133 235 306 140 267
Investments 34 9 9 16 26 136 87 120 310 505 989 626 760
1,255 1,455 1,683 1,729 1,723 1,746 2,003 2,422 2,756 3,254 3,924 5,105 5,769
Total Assets 2,327 2,697 3,211 3,812 3,892 3,960 4,116 4,549 5,258 6,066 7,622 8,623 11,384

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
354 389 522 468 709 282 341 501 570 1,090 856 806
-280 -260 -369 -689 -218 -149 -135 -165 -509 -521 -851 -725
-72 -83 -136 251 -462 -159 -130 -183 -137 -306 427 507
Net Cash Flow 2 46 18 29 29 -26 75 153 -76 264 432 588

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Debtor Days 54 54 50 41 57 58 67 66 71 55 57 58
Inventory Days 268 247 272 293 289 290 286 316 294 337 337 276
Days Payable 95 89 110 97 145 130 137 154 135 140 101 83
Cash Conversion Cycle 227 212 213 237 200 218 216 228 229 251 293 251
Working Capital Days 117 112 98 106 84 94 107 109 113 119 127 119
ROCE % 24% 24% 28% 14% 5% 9% 10% 16% 19% 31% 20% 11%

Shareholding Pattern

Numbers in percentages

1 Recently
Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023
46.29% 46.29% 46.29% 46.29% 46.29% 46.29% 46.29% 46.29% 46.29% 46.29% 46.29% 46.29%
17.47% 17.81% 18.46% 12.34% 11.02% 10.61% 10.57% 10.46% 10.58% 10.05% 9.86% 10.27%
24.82% 25.12% 25.24% 30.02% 32.70% 33.49% 33.46% 33.71% 33.74% 34.86% 34.72% 34.19%
0.28% 0.22% 0.22% 0.24% 0.24% 0.24% 0.32% 0.32% 0.32% 0.32% 0.32% 0.32%
11.14% 10.57% 9.80% 11.11% 9.75% 9.37% 9.34% 9.22% 9.06% 8.46% 8.80% 8.93%
No. of Shareholders 1,00,6261,05,42895,2391,06,7791,15,3351,10,8181,11,0431,08,1771,10,29699,88995,93082,809

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Concalls